PT-141 Cost in the US

Why there’s no single PT-141 price

Search “PT-141 cost” and you’ll see numbers ranging from under a hundred dollars to nearly three hundred dollars a dose. That spread isn’t noise — it reflects something unusual about PT-141 that most wellness peptides don’t share: it exists in two completely different legal forms at the same time, and they’re priced on entirely different logic.

PT-141 is the research name for bremelanotide. One version of bremelanotide is Vyleesi, an FDA-approved, brand-name finished drug — a prefilled, single-use autoinjector sold by a manufacturer through a designated specialty pharmacy, approved only for premenopausal women with hypoactive sexual desire disorder (HSDD). The other version is compounded bremelanotide, mixed by a licensed pharmacy to a prescriber’s order, used off-label by everyone the approved product doesn’t cover — men, postmenopausal women, and anyone whose provider prescribes a different delivery form.

The result is a cost picture that runs backwards from what you’d expect. With most medications, the FDA-approved product is the one insurance covers and the compounded version is a fringe alternative. With PT-141, the approved product (Vyleesi) is the most expensive route by a wide margin — and yet it’s the only route insurance will ever touch. Understanding that inversion is the whole story of what PT-141 costs.

Note: This page is about pricing, not protocols. It does not provide dosing instructions or tell you where to source unregulated product — only how the cost lands across the legitimate routes and what drives the differences.

The number that actually matters: per use, not per month

Before comparing routes, fix the right unit. Most peptides people price-compare — GLP-1 weight-loss drugs, growth-hormone secretagogues, repair peptides — are used on a daily or weekly schedule, so “cost per month” is the meaningful figure. PT-141 isn’t like that. It’s an on-demand compound: used ahead of an intended occasion, not on a standing schedule, and with a hard ceiling on how often it can be used in a day or a month.

That changes the budgeting math entirely. A supply that contains several doses might last a daily-medication user a few weeks, but for an occasional PT-141 user it can stretch across months. So a quote that sounds expensive as a one-time number can be inexpensive per actual use — and a “cheap monthly subscription” framing can be misleading if you’d only use a fraction of what it ships.

The single most useful question to ask any provider is therefore not “how much per month?” but “how many doses does this price include, and how long will that realistically last me?” Two quotes can look identical on the price tag and differ several-fold once you divide by usable doses.

What you’re actually paying for

Whichever route you take, a PT-141 bill is rarely just the medication. It usually bundles four things, and the cheapest line item is almost always the drug itself:

• The medication. The active ingredient is the small part. Even branded Vyleesi’s cost is driven more by being a finished, single-source specialty product than by the quantity of peptide inside it.
• The prescriber relationship. PT-141 is prescription-only on every legitimate route. Someone licensed has to evaluate you — and because bremelanotide can transiently raise blood pressure, a real evaluation includes a cardiovascular screen, not just a checkout quiz. That clinician time is built into the price.
• The pharmacy and delivery form. A prefilled autoinjector, a compounded nasal spray, a troche, and a compounded injectable vial are different products to make and dispense, and they’re priced differently.
• Channel legitimacy. The invisible line item. A LegitScript-certified telehealth platform working with a licensed compounding pharmacy costs more than an anonymous vendor — because the oversight, sourcing, and accountability you’re paying for are exactly what the cheap option strips out.

Route 1 — Vyleesi: the approved product (and the priciest)

Vyleesi is the only FDA-approved formulation of bremelanotide. Because it’s a branded, single-source drug dispensed through one specialty-pharmacy channel, its sticker price is the highest of any route. At cash price, a single-dose pen runs in the region of $290, and full retail packs of four pens commonly sit well over $1,000 before any discount. Standard pharmacy discount cards generally don’t apply to it the way they do to ordinary generics, because of how it’s distributed.

But Vyleesi is also the only PT-141 route where insurance can do real work. For its approved population, roughly 70% of commercial plans provide some coverage, although many require prior authorization first. On top of that, the manufacturer runs a copay-assistance program that can bring eligible, commercially insured patients’ out-of-pocket cost down dramatically — in some cases to little or nothing per dose. Government plans and uninsured patients don’t get that benefit, and off-label use is not covered, which matters because most people interested in PT-141 fall outside the approved indication entirely.

So the honest summary of Vyleesi cost is: high list price, but potentially the cheapest net route for a premenopausal woman with HSDD and the right insurance — and an expensive, fully out-of-pocket route for anyone else.

Route 2 — Compounded bremelanotide through telehealth

This is the route most people actually mean when they ask about “PT-141 cost,” because it’s the one open to men and to women outside the Vyleesi indication. A telehealth platform connects you with a licensed provider, and if appropriate, a compounding pharmacy prepares bremelanotide to that prescription. It comes in several forms, each priced a little differently:

• Compounded nasal spray — a needle-free option, commonly advertised in the region of $150–$200 per month of supply.
• Troches / sublingual — sometimes the lowest unit cost; one common offering is around $220 for a 20-piece supply, often available as a one-off or subscription.
• Compounded injectable — typically in a similar band to the above, sold as a multi-dose vial.

To those product prices, add any consultation or intake fee, which ranges from $0 (bundled into the product) to roughly $150 for a standalone telehealth visit. Crucially, none of this is insurance-eligible — compounded products aren’t covered, and discount cards don’t apply.

The reason this route can still work out cheaper than Vyleesi for the right buyer comes back to the per-use point: a multi-dose compounded supply spread across an occasional-use pattern can land at a low effective cost per occasion, even though it’s fully out of pocket.

Route 3 — Research-only vials: why “cheapest” is misleading

You will find bremelanotide sold as research-only “RUO” vials at a fraction of any clinical price — sometimes in the $35–$80 per 10 mg range. On a per-milligram basis that’s by far the lowest number on this page, and that’s exactly why it’s worth being clear-eyed about.

These vials are labeled not for human use. There’s no prescriber, no pharmacy compounding standards, no verified concentration or purity, and no recourse if the contents aren’t what the label claims. A low price on an injectable of unknown strength and unknown purity isn’t a saving — it’s the cost being moved off the receipt and onto your safety. This is not a patient route, and a rock-bottom price tag is itself one of the clearer warning signs.

Does insurance ever pay?

For peptides in general, the realistic answer is no — wellness and anti-aging peptides are essentially never covered, which is why this whole category is a cash market. PT-141 is the rare partial exception, and only because Vyleesi is a genuine FDA-approved drug: for premenopausal women with HSDD, a commercial plan may cover it (often with prior authorization), and the manufacturer copay program can cut the out-of-pocket cost further.

That exception is narrow. It doesn’t extend to compounded bremelanotide, to Vyleesi used off-label, or to men. HSA and FSA funds may be usable for a legitimate, prescribed expense, but that’s account-specific and not guaranteed — worth checking with your plan rather than assuming.

How to read a PT-141 price quote

Because the same dollar figure can mean very different value, a few habits help you compare like with like:

• Convert everything to cost per use. Ask how many doses a quote contains, then divide. That single step makes a “$220 supply” and a “$290 dose” directly comparable for your usage pattern.
• Separate the medication from the service. A higher price that includes a real provider evaluation, a blood-pressure screen, and a licensed compounding pharmacy is buying something the cheap option doesn’t.
• Treat a too-low price as a flag, not a win. No-evaluation, instant-script, or RUO-as-prescription offers are cutting exactly the costs that keep the product legitimate.
• Match the route to who you are. A premenopausal woman with HSDD and commercial insurance may find approved Vyleesi cheapest net; almost everyone else is comparing out-of-pocket compounded options, where form and dose count drive the real cost.

Prices and coverage in this space move quickly, so treat the figures here as current-as-of-2026 reference points rather than fixed quotes, and confirm specifics with a licensed provider and your own plan. For the mechanics of which route you’re eligible for in the first place, see how to get PT-141 and the prescription walkthrough — this page is only about what each route costs once you’re on it.